Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
Mogamulizumab
Sézary syndrome
cutaneous T-cell lymphoma
mycosis fungoides
prior systemic therapy
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
27
7
2021
medline:
15
4
2022
entrez:
26
7
2021
Statut:
ppublish
Résumé
Patients with mycosis fungoides (MF) and Sézary syndrome (SS) often require multiple lines of systemic therapy. In the phase 3 MAVORIC study (NCT01728805), mogamulizumab demonstrated superiority to vorinostat in median progression-free survival (PFS) and confirmed overall response rate (ORR) in patients with MF/SS. This
Identifiants
pubmed: 34304674
doi: 10.1080/10428194.2021.1953007
pmc: PMC9447791
mid: NIHMS1830170
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Vorinostat
58IFB293JI
mogamulizumab
YI437801BE
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3109-3118Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Oncotarget. 2014 Aug 30;5(16):6558-72
pubmed: 25115382
J Clin Oncol. 2015 Nov 10;33(32):3766-73
pubmed: 26438120
Dermatol Clin. 2015 Oct;33(4):731-45
pubmed: 26433845
Clin Cancer Res. 2004 Aug 15;10(16):5494-500
pubmed: 15328188
Ann Rheum Dis. 2001 Aug;60(8):729-35
pubmed: 11454634
Nat Rev Rheumatol. 2016 Dec;12(12):731-742
pubmed: 27784891
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
J Clin Oncol. 2015 Nov 10;33(32):3759-65
pubmed: 26261247
Blood. 2011 Jan 27;117(4):1205-17
pubmed: 20956800
Cancer. 2006 Nov 15;107(10):2504-11
pubmed: 17048251
J Invest Dermatol. 2002 Dec;119(6):1405-10
pubmed: 12485447
Lancet Oncol. 2018 Sep;19(9):1192-1204
pubmed: 30100375
Haematologica. 2018 Jan;103(1):126-135
pubmed: 29025909
J Clin Med. 2019 Sep 27;8(10):
pubmed: 31569769
Ther Adv Hematol. 2016 Jun;7(3):171-4
pubmed: 27247757
Blood. 2008 Oct 15;112(8):3082-7
pubmed: 18647960
Clin Cancer Res. 2012 Sep 15;18(18):5051-60
pubmed: 22850569
Biomed Res Int. 2013;2013:932010
pubmed: 24163824
Br J Dermatol. 2009 Mar;160(3):519-26
pubmed: 19067706
Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):637-643
pubmed: 27637428
Invest New Drugs. 2010 Dec;28 Suppl 1:S3-20
pubmed: 21161327
Br J Dermatol. 2020 Mar;182(3):770-779
pubmed: 31049926
Clin Cancer Res. 2010 Mar 1;16(5):1520-31
pubmed: 20160057
Eur J Cancer. 2017 May;77:57-74
pubmed: 28365528
Eur Rev Med Pharmacol Sci. 2018 Jun;22(11):3586-3594
pubmed: 29917213
Oncotarget. 2017 Apr 4;8(14):24031-24044
pubmed: 28199990
Am J Hematol. 2012 Apr;87(4):354-60
pubmed: 22367792
Br J Dermatol. 1983 Apr;108(4):451-6
pubmed: 6838769
Biomed Res Int. 2014;2014:265840
pubmed: 25313353
Lancet. 2017 Aug 5;390(10094):555-566
pubmed: 28600132
J Clin Oncol. 2011 Jun 20;29(18):2598-607
pubmed: 21576639
Arch Dermatol. 2005 Mar;141(3):325-30
pubmed: 15781673
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
Blood. 2007 Sep 15;110(6):1713-22
pubmed: 17540844
Front Med (Lausanne). 2018 Aug 27;5:236
pubmed: 30211164
Blood. 2015 Jan 1;125(1):71-81
pubmed: 25336628
J Rheumatol. 1998 Mar;25(3):433-40
pubmed: 9517759
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv30-iv40
pubmed: 29878045